Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 169, Issue 12, Pages 1256-1266Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2012.12010087
Keywords
-
Categories
Funding
- Alcobra
- Shire
- NIH
- Eli Lilly
- Janssen
- McNeil
- Novartis
- Pfizer
- Elminda
- Fundacion Areces
- Medice Pharmaceuticals
- Spanish Child Psychiatry Association
- Abbott
- Alza
- AstraZeneca
- Bristol-Myers Squibb
- Celltech
- Cephalon
- Esai
- Forest
- GlaxoSmithKline
- Gliatech
- Merck
- NARSAD
- National Institute on Drug Abuse
- New River
- National Institute of Child Health and Human Development
- NIMH
- Noven
- Neurosearch
- Organon
- Otsuka
- Pharmacia
- Prechter Foundation
- Stanley Foundation
- UCB Pharma
- Wyeth
- Primedia/Massachusetts General Hospital Psychiatry Academy
- Boehringer-Ingelheim
- Sepracor
- UCB (Schwarz) Pharma
Ask authors/readers for more resources
Objective: The existence of comorbidity between attention deficit hyperactivity disorder (ADHD) and bipolar I disorder has been documented in clinical and epidemiological studies, in studies of children and adults, and in diagnosed ADHD and bipolar I patient samples. Yet questions remain about the validity of diagnosing bipolar I disorder in ADHD youth. The authors aim to clarify these issues by reviewing family genetic studies of ADHD and bipolar I disorder. Method: The authors applied random-effects meta-analysis to family genetic studies of ADHD and bipolar I disorder. Twenty bipolar proband studies provided 37 estimates of the prevalence of ADHD in 4,301 relatives of bipolar probands and 1,937 relatives of comparison probands. Seven ADHD proband studies provided 12 estimates of the prevalence of bipolar I disorder in 1,877 relatives of ADHD probands and 1,601 relatives of comparison probands. Results: These studies found a significantly higher prevalence of ADHD among relatives of bipolar probands and a significantly higher prevalence of bipolar I disorder among relatives of ADHD probands. These results could not be accounted for by publication biases, unusual results from any one observation, sample characteristics, or study design features. The authors found no evidence of heterogeneity in the ADHD or bipolar family studies. Conclusions: The results suggest that ADHD plus bipolar comorbidity cannot be accounted for by misdiagnoses, but additional research is needed to rule out artifactual sources of comorbidity. More research is also needed to determine whether comorbidity of ADHD and bipolar I disorder constitutes a familial subtype distinct from its constituent disorders, which if confirmed would have implications for diagnostic nosology and genetic studies. (Am J Psychiatry 2012; 169:1256-1266)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available